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Abstract
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive
pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs. The objectives of this study were to
quantify the economic burden of ADRs and to estimate the breakeven cost of pre-emptive PGx testing in Singapore. We
collected itemized costs for 1000 random non-elective hospitalizations of adults admitted to a tertiary-care general hospital in
Singapore. The presence of ADRs at admission and their clinical characteristics were reported previously. The economic
burden of ADRs was assessed from two perspectives: (1) Total cost and (2) incremental costs. The breakeven cost of PGx
testing was estimated by dividing avoidable hospitalization costs for ADRs due to selected drugs by the number of patients
taking those drugs. The total cost of 81 admissions caused by ADRs was US$570,404. Costs were significantly higher for
bleeding/elevated international normalized ratio (US$9906 vs. US$2251, p= 6.58 × 10−3) compared to other ADRs, and for
drugs acting on the blood coagulation system (US$9884 vs. US$2229, p= 4.41 × 10−3) compared to other drug classes.
There were higher incremental laboratory costs due to ADRs causing or being present at admission. The estimated breakeven
cost of a pre-emptive PGx test for patients taking warfarin, clopidogrel, chemotherapeutic and neuropsychiatric drugs was
US$114 per patient. These results suggest that future studies designed to directly measure the clinical and cost impact of a
pre-emptive genotyping program will help inform clinical practice and health policy decisions.
Introduction
Adverse drug reactions (ADRs) are known to contribute to
worse patient outcomes and increased hospital admissions
[1]. We have previously reported a prospective study in
1000 random non-elective hospitalizations of adults
admitted to a tertiary acute care hospital in Singapore, a
multiethnic island city state in Southeast Asia, and found
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that 12.4% of patients have at least one ADR at admission
and 8.1% of admissions were caused by an ADR [2]. Data
on ADR-associated costs in Singapore are scant. In a recent
study, ADRs were identified using International Classifi-
cation of Diseases (ICD) codes in patients ≥ 65 years old,
and the median hospitalization cost per patient with ADRs
was estimated to be $1015 (2013 SGD, approximately US
$811) [3]. On the higher end, the median cost of hospita-
lization for chemotherapy-induced febrile neutropenia in
cancer patients was $3964 (2012 SGD, approximately US
$3171) [4]. The cost of other ADRs in the general popu-
lation is unknown.
Studies in the Netherlands, Germany, and Canada have
documented substantial annual national ADR-related costs
in the order of 1050 million Deutsche Mark (DM) (~US
$732 million in 1995), €355 million (~US$441 million in
2004), and Canadian $35.7 million (~US$33.3 million in
2007), respectively [5–7]. In the Netherlands, the direct cost
attributable to ADRs constitutes 2.4% of the national
healthcare budget [6]. In India, the absolute ADR-related
costs were much lower than in developed countries, likely a
reflection of the lower cost of living there. However, the
average cost per patient hospitalized with an ADR (US$
115) was higher than the national per capita annual health
expenditure (US$ 109) [8]. Hence, it is vital to design
strategies to reduce cost burden associated with ADRs.
Our team previously conducted a prospective study on
1000 randomly selected adults admitted non-electively to a
large tertiary hospital to evaluate the presence of ADRs at
the point of admission. The prevalence of ADRs at admis-
sion was 12.4% and that of ADRs causing the admission
was 8.1%. Furthermore, 30 of the 81 ADRs causing
admission had a pharmacogenetic (PGx) association, sug-
gesting a potential for prevention through PGx testing [2].
Most initial efforts to implement PGx have been on a
reactive single-variant basis at the point of drug prescrip-
tion, which may not provide the needed information in a
timely fashion and incurs a cost for each test of a different
variant. Pre-emptive PGx programs, where multiple genetic
variants are genotyped and stored in electronic medical
records prior to drug prescription, is an alternative strategy
that is more practical and likely more cost-effective than
reactive, single-variant genotyping [9]. Experience shared
by the early adopters of pre-emptive PGx testing revealed
some variation in its implementation, such as the panel
used, patient population tested and so on [9]. As this pre-
emptive strategy is still in its infancy, it is not currently
covered by insurance [10]. More studies to evaluate the
clinical outcomes, cost-effectiveness and to define target
populations will be needed to support regulatory and payer
decisions on pre-emptive PGx testing [11].
In Singapore, genotyping for HLA-B*15:02 allele is
performed prior to initiation of carbamazepine therapy in
patients of Asian ancestry as standard of care for the
avoidance of Steven’s Johnson Syndrome and Toxic Epi-
dermal Necrolysis (SJS/TEN) [12]. A cost-effectiveness
analysis supported the decision by the Ministry of Health to
subsidize the cost of the genotyping test. As a result, the
number of cases of carbamazepine-associated SJS/TEN has
dropped sharply from an average of 18 cases per year to
only one case over 4 years after the implementation of HLA-
B*15:02 testing [12]. This precedent may herald more of
such PGx tests that demonstrate both clinical efficacy and
cost-effectiveness. However, multiple single drug-gene tests
incur repeated fixed costs such as blood collection, DNA
extraction, PCR amplification that could be avoided through
multiple allele genotyping panels and next generation
sequencing. The genetic information would also be avail-
able at the time of prescribing, rather than having to wait for
return of results from single-gene tests. As such, the future
is trending towards pre-emptive PGx panel testing.
Most cost-effectiveness analyses (CEA) of PGx testing
conducted thus far have been for single drug-gene pairs. One
study found a one-time PGx test for a panel of markers cost-
effective for preventing lifetime ADRs at a price of US$1102
per test [13]. This study, however, did not include costs of
alternative drugs for patients found to be unsuitable for the
standard treatments based on genotype and the variability of
hospitalization costs for different ADRs. To the best of our
knowledge, detailed modeling of all possible outcomes in a
PGx testing scenario for a CEA beyond one single drug-gene
pair has not been done, likely due to its extreme complexity.
Encouragingly, 75% of pharmacoeconomic evaluations of
PGx testing favored it [14] and a discrete-choice experiment
in Singapore showed that majority of patients were willing to
pay several hundred dollars out-of-pocket for PGx tests to
reduce ADR risk [15]. Given the expanding knowledgebase
of associations between genetic variation and safe and effi-
cacious use of drugs [16], there is a growing interest in
quantifying the economic costs and benefits of pre-emptive
PGx testing [17].
The objectives of this study were twofold. First, we
aimed to quantify the economic burden of ADRs in the
general adult population in Singapore. The total as well as
incremental costs associated with ADRs were investigated.
Second, we aimed to gauge the potential of a pre-emptive
PGx program for prevention of ADRs in Singapore, by
estimating the breakeven cost of pre-emptive PGx testing.
Materials and methods
Patient population
Details of patient recruitment, data collection and ADR
ascertainment were described previously [2]. Briefly, the
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patient cohort consisted of 1000 randomly selected adults
admitted non-electively to the Singapore General Hospital
(SGH), the largest acute care hospital in Singapore.
Demographic and clinical information were collected, and
each patient was screened for ADRs at admission based on
the drugs taken before admission and the presenting com-
plaints. Suspected ADRs were formally assessed by two
investigators using the Liverpool Causality Assessment
Tool (LCAT), an algorithm that classifies ADRs into one of
four categories (definite, probable, possible and unlikely)
based on a series of up to ten questions about the char-
acteristics of the ADR [18]. We evaluated 351 potential
ADRs in 254 out of 1000 admissions using the LCAT, but
included only ‘definite’ and ‘probable’ ADRs (higher cer-
tainty that reaction was linked to suspected drug) in the
prevalence calculations and subsequent analyses for a more
conservative estimation [2]. Itemized bills were retrieved
from the finance billing database of SGH for all 1000
patients. The bills reflect the amount before any patient
subsidy and represents the cost to the health system. This
study was approved by the ethics committee of SGH with
waiver of informed consent.
Economic analysis
All analyses were undertaken from a health system per-
spective, thus prices before any government subsidy were
used in all calculations. Only direct medical costs related to
hospital admissions were considered, as this is known to be
the largest cost item. All costs were converted to US$ using
2016 exchange rates (US$1= SGD 1.382) [19].
Total cost of ADRs
The total cost of ADRs was the sum of costs of hospita-
lizations caused by ADRs. We then further stratified based
on demographic, clinical and ADR characteristics (e.g.,
causality, severity, PGx association, etc) to understand the
nature of the ADRs that posed the greatest economic
burden. Given the variety of ADRs, we performed a
subgroup analysis on the five most common ADR types
and suspected drug classes. The Wilcoxon signed rank
test or Spearman rank correlation were used as
appropriate.
Incremental costs of ADRs
To estimate the incremental economic burden due to the
presence of ADRs at the point of admission, we compared
the cost differences for two groups of patients (admissions
caused by ADRs, and admissions presenting with but not
caused by ADRs) with controls (admissions without
ADRs). For both groups of cases, we performed propensity
score matching to select controls. For the propensity score
model, all demographic and clinical variables were included
with exact matching imposed for ward type, place of
admission (emergency department or specialist outpatient
clinics), having a cardiovascular condition, having cancer
and Charlson’s comorbidity index (CCI). These variables
were chosen for exact matching as they had the greatest
effect on cost. CCI was calculated from clinical information
collected at admission [20]. Propensity score matching was
performed using the nearest-neighbour method with a
caliper of 0.25 standard deviations and a ratio of one.
Alternative propensity score models were explored, and this
final model was chosen because of better matching of
important characteristics and overall propensity scores. All
models explored are shown in Tables S1 and S2. The cost
difference between cases and controls was analyzed using
the Wilcoxon sign rank test and expressed as the median of
differences between each matched pair. We also analyzed
differences by different cost categories (ward, drugs, labs,
other investigations, treatments and procedures, service and
facility fees, and consumables). Propensity score matching
was performed using the MatchIt package version 3.0.1 in R
version 3.3.3 [21].
Estimation of breakeven cost of PGx testing
We performed a simple estimation of the maximum cost of
a hypothetical PGx panel testing at which the savings from
avoiding ADR associated hospitalizations will be offset.
Out of the 81 admissions caused by ‘definite’ or ‘probable’
ADRs in our previous study of 1000 adults admitted non-
electively, 30 involved a drug-gene pair with a PGx asso-
ciation [2] with levels of evidence between 1A and 3
according to PharmGKB. We limited this hypothetical PGx
panel to drug-gene pairs for which there are data on efficacy
from prospective trials of PGx testing vs. no testing, i.e.
warfarin, clopidogrel, chemotherapeutic and neuropsychia-
tric (anti-depressants, anti-psychotics and anxiolytics)
drugs. The potential savings from avoided ADRs was
estimated by the sum of the product of efficacy of PGx
testing and total cost of ADRs due to each drug(s) within
the previous ADR study [2]. This amount was then extra-
polated to the entire Singapore population over a year,
assuming 63% of all adult admissions are non-elective
(estimated from recruitment statistics from a previous sur-
vey performed in Singapore [2]). We then estimated the
number of patients at risk of ADRs (number of patients
taking at least one of the drugs mentioned) in the entire
Singapore population (residents and non-residents) in 2016
using disease incidence or prevalence data for the common
indications of those drugs. The indications were considered
individually, so the estimated total number of patients at
risk of ADRs (and therefore number of patients to be tested)
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is the sum of patients with each indication. The breakeven
cost was then the potential savings from ADR avoidance
divided by the number of patients at risk of ADRs due to the
four drugs/drug classes. All analyses were carried out in R
version 3.3.3 [22].
Results
Out of 1000 admissions, 124 had an ADR present at the
point of admission, of which 81 were caused by the ADR
[2]. Cost data were retrievable for 995 out of 1000 admis-
sions, including all 124 admissions with ADRs at admis-
sion. The median hospitalization cost was US$2800 (range,
US$416–U$82489).
Total cost of ADRs
The total cost of the 81 admissions caused by ADRs was
US$570,404, constituting 10.1% of the total hospitaliza-
tion cost of the 995 patients. The median cost for these
admissions was US$2951 (range, US$591–US$81,476).
Table 1 showed the breakdown by different cost cate-
gories. Table 2 showed the differences in cost by various
demographic, clinical and ADR characteristics. Among
these admissions, cost was significantly higher for surgi-
cal disciplines (p= 0.031) and higher CCI (p= 2.4 × 10
−4). Among ADR characteristics, there was a trend
towards higher costs with higher number of ADRs
(p= 0.046), significantly higher costs for drug-ADR pairs
with PGx association (p= 0.027) and with higher severity
of the ADRs (p= 8.62 × 10−4). Of the top five ADR types
and drug classes, costs were significantly higher with
bleeding/elevated international normalized ratio (INR)
(US$9906 vs. US$2251, p= 6.58 × 10−3) and drugs act-
ing on the blood coagulation system (US$9884 vs. US
Table 1 Total cost of ADRs by categories of expenses
Category Total (US$)
Drugs $49,762
Laboratory investigations $108,315
Other investigations $81,426
Treatments and procedures $66,993
Service and facility feesa $51,643
Consumables and miscellaneous $38,934
Wardb $173,329
Total $570,404
This table shows the total cost for the 81 patients with admissions
caused by ADRs, rounded to the nearest dollar.
aIncludes professional fees
bBed charges only. Does not include daily treatment fee, procedures,
medications, laboratory tests, imaging, etc.
Table 2 Total cost of admissions caused by ADRs by demographic,
clinical and ADR characteristics
Variable N US$, median p
Demographic and clinical
Age Spearman’s rho = −0.225 0.043
Gender Male 44 $3848 0.166
Female 37 $2229
Ethnicity Chinese 57 $2748 0.563
Malays 10 $5897
Indians 12 $2867
Others 2 $4894
Have drug allergies Yes 26 $2766 0.667
No 55 $3024
Ward type Medical 72 $2766 0.031
Surgical 9 $9903
Admitted from ED 60 $2987 0.751
SOC 21 $2823
Have a cardiovascular
conditiona
Yes 67 $3059 0.473
No 14 $2035
Have cancer Yes 16 $4041 0.371
No 65 $2823
Charlson’s
comorbidity index
Spearman’s rho = 0.415 1.16 x 10−4
No. of drugs taken
before admission
Spearman’s rho = 0.263 0.018
ADR characteristics
No. of ADRs 1 75 $295 0.046
2 4 $8533
3 2 $812
Drug-ADR pair has
PGx associationb
Yes 30 $4819 0.027
No 51 $2229
Causalityc Definite 24 $4410 0.566
Probable 57 $2783
Avoidabilityc Definitely 3 $7766 0.614
Possibly 76 $2987
Not
avoidable
2 $2643
Severityc 1-2 4 $1690 8.62 x 10−4
3–4 68 $2625
5–6 9 $16,724
Typec A 79 $2951 0.420
B 2 $7789
p values were from Wilcoxon signed rank test or Spearman’s rank
correlation, as appropriate, to test for the association between various
variables and total cost among the 81 admission caused by ADRs. The
Spearman’s rank correlation measures the strength and direction of
correlation between two ranked variables and a higher absolute value
represents higher correlation. p values < 0.05 were considered
statistically significant (bolded).
ADR adverse drug reaction, ED emergency department, PGx
pharmacogenetic, SOC specialist outpatient clinics
aAt least one of the following conditions: hypertension, hyperlipidae-
mia, congestive heart failure, history of myocardial infarction,
ischemic heart disease, rheumatic heart disease, atrial fibrillation,
coronary artery disease and any arrhythmias.
bThis refers to a PGx association for the ADR caused.
cCausality, avoidability, severity and type were assessed using the
Liverpool Causality Assessment Tool [18], the method of Hallas et al.
[39], the adapted Hartwig scale [40] and the classification of Rawlins
and Thomson [41], respectively. Severity increases with number.
Type A ADRs are dose dependent and predictable while type B are
not.
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$2229, p= 4.41 × 10−3), respectively (Table 3). As war-
farin and clopidogrel (the main drugs within the class) are
well known to cause bleeding and elevation of INR
(warfarin only) and have PGx associations for these
clinically important ADRs, the associations for drug
classes and PGx associations were likely driven by these
ADRs (Figure S1).
Incremental cost of ADRs
For admissions caused by ADRs, 76 of 81 patients were
matched using the propensity score model. Baseline char-
acteristics before and after matching are shown in Table S1.
The total cost of admissions caused by ADRs was not
significantly different from admissions without ADRs (p=
0.243), but laboratory costs (such as renal function tests, full
blood count, serum electrolytes, and prothrombin time)
were significantly higher (median of differences=US$187,
p= 0.005) (Table 4).
To determine if the presence of an ADR at admission
for other causes contributed to increased cost, we also
compared the costs for admissions with but not caused by
ADRs with those for admissions without ADRs. For these
admissions, 37 of the 43 patients were matched using the
propensity score model. Characteristics of patients before
and after matching are shown in Table S2. Again, the total
cost of cases was not significantly different from the
controls (p= 0.561) but laboratory costs were higher in
admissions with but not caused by ADRs (median of
differences=US$283, p= 0.014) (Table 4).
Breakeven cost of pre-emptive PGx testing
The total cost of the 30 admissions caused by ADRs with a
PGx association with the suspected drug was US$214,902.
Considering only ADRs due to warfarin, clopidogrel, che-
motherapeutic and neuropsychiatric drugs, the total cost of
admissions were US$86,650, US$38,621, US$63,276 and
US$6368, respectively. Using median PGx efficacies of
31.5% [23–26], 38.4% [27, 28], 80.8% [29], and 47.2%
[30], respectively, the total cost potentially avoidable by
PGx testing was US$96,258. The estimated number of
patients taking at least one drug from the above mentioned
list was 247,988 (Table S3). In a hypothetical situation, if
all these patients had undergone pre-emptive PGx testing,
the breakeven cost of the test would be US$114 per person
tested (Table 5).
Discussion
We have quantified the direct economic burden of hospi-
talizations caused by ADRs in the general adult population.
At a rate of US$570,400 per 1000 patients, the direct annual
ADR burden in Singapore is estimated to be US$168 mil-
lion, almost 5% of the annual operating healthcare expen-
diture [31]. The median cost of US$2951 was also much
higher than the SGD1015 (~US$734) reported previously in
elderly patients from the same institution, likely because of
different ADR detection methods (ICD codes vs. manual
review) [3]. In this study, bleeding and/or elevated INR due
Table 3 Total cost of admissions
caused by top five ADR types
and drug classes
N Median (range), US$ p
Yes No
ADR type
Gastrointestinal 18 $1997 ($710–$81,476) $3024 ($591–$40,311) 0.385
Bleeding/elevated INR 15 $9906 ($1413–$19,327) $2251 ($591–$81,476) 6.58× 10−3
Electrolyte abnormalities 8 $1656 ($783–$6028) $3024 ($591–$81,476) 0.157
Infection/sepsis 6 $4749 ($1632–$40,311) $2823 ($591–$81,476) 0.422
Hypotension 6 $2142 ($783–$4381) $3059 ($591–$81,476) 0.245
Drug classa
Cardiovascular 23 $2229 ($783–$18,907) $3352 ($591–$81,476) 0.376
Blood 17 $9884 ($1413–$19,327) $2229 ($591–$81,476) 4.41× 10−3
Chemotherapeutic 15 $4438 ($591–$40,311) $2887 ($710–$81,476) 0.447
Central nervous system 12 $3525 ($842–$30,195) $2951 ($591–$81,476) 0.755
Musculoskeletal 6 $4804 ($842–$18,907) $2951 ($591–$81,476) 0.921
p values were from Wilcoxon signed rank test. p values < 0.05 were considered statistically significant
(bolded).
ADR adverse drug reaction, INR international normalized ratio
aSuspected drugs were classified according to the Anatomical Therapeutic Chemical (ATC) classification
system [42].
Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults
to anticoagulants or anti-platelets were identified to be the
most expensive ADRs. Therefore, efforts to reduce ADRs
with these agents are likely to provide the most impact in
reducing costs. It should be highlighted that evidence of
clinical efficacy of PGx testing is also among the most
abundant for this group of ADRs. Failing to act is likely to
result in a missed opportunity.
Admissions caused by ADRs as well as admissions with
but not caused by ADRs did not incur significantly higher
total costs than admissions without ADRs. However,
laboratory costs were higher in both groups, likely because
of additional laboratory tests required to monitor the ADR
until its resolution, such as in the case of over-antic-
oagulation, electrolyte abnormalities, renal impairment,
bone marrow suppression and infection, which made up
about half of the ADRs that caused admission.
Over one-third of the ADRs captured in our study had a
PGx association, and warfarin, clopidogrel, chemother-
apeutic or neuropsychiatric drugs were responsible for 76%
of these ADRs. We propose that PGx testing is one avenue
towards safer use of these drugs. It has been argued that pre-
emptive PGx testing would be more convenient and
cost-effective than individual PGx tests administered on a
reactive basis [32]. The prevalence of actionable genotypes
is >90% across multiple ethnicities [33]. Among Singa-
poreans, the prevalence of at risk genotypes for warfarin
alone is also about 90% [34] but PGx testing for warfarin is
not routinely performed. Thus, we have also attempted to
estimate the breakeven point at which the cost of pre-
emptive PGx testing would equal potential savings for
patients receiving drugs with well-established PGx asso-
ciations. To the best of our knowledge, this is the first study
exploring the economics of PGx testing in this way.
Hypothetically, if patients requiring warfarin, clopidogrel,
chemotherapeutic or neuropsychiatric drugs were pre-
emptively tested, the price of the test only needed to be
<US$114 to be cost saving at a health systems level. The
current price of pre-emptive genotyping panels ranges from
US$300 to $2000 [35]. The optimal strategy for pre-
emptive PGx testing is still unclear. In our calculations we
assume that all patients needing the four drugs/drug classes
could be given PGx testing before the drug is administered,
perhaps at the point of diagnosis of the condition. Practi-
cally, another approach may be testing patients likely to
receive the drugs, based on their risk factors, but the
assessment of the most cost-beneficial strategy is beyond
the scope of this study.
This estimate is likely to be conservative for several
reasons. Firstly, costs due to other drugs with PGx asso-
ciations, costs attributable to ADRs that did not cause
hospital admissions, indirect costs and benefits beyond the
current admission were not included in the calculation.
Secondly, costs due to adverse outcomes avoided from
better response to alternative drugs or optimal doses of
drugs were also not included, such as adverse cardiovas-
cular outcomes due to inadequate clopidogrel response,
which is associated with a patient’s CYP2C19 genotype
[36]. Among the 111 patients taking clopidogrel prior to
admission in our cohort, 10 were admitted for myocardial
infarction, stroke or thrombosis. While the CYP2C19 gen-
otypes of these patients are unknown, it is possible that
some of these events and their associated costs could have
been prevented by PGx testing. Thirdly, the number of
patients to test could be over-estimated as some patients
Table 4 Incremental costs of
ADRs
Cost type Admissions caused by ADRs Admissions with but not caused by
ADRs
Median of differences (95%
CIa), US$
p Median of differences (95%
CIa), US$
p
Total $345 (−$496–$2500) 0.243 −$9 (−$1503–$4264) 0.561
Drugs $48 (−$17–$147) 0.100 −$8 (−$103–$119) 0.941
Laboratory investigations $187 ($90–$652) 0.005 $283 ($99–$1020) 0.014
Other investigations $20 (−$144–$377) 0.412 $212 (−$56–$648) 0.118
Treatments and
procedures
$26 (−$98–$350) 0.329 $62 (−$148–$530) 0.265
Ward $77 (−$47–$839) 0.104 $57 (−$386–$1291) 0.455
Service and facility fees $0 (−$137–$204) 0.903 $0 (−$305–$898) 0.874
Consumables and misc −$5 (−$72–$96) 0.912 $7 (−$119–$533) 0.747
The table shows the median of the differences in cost between each pair of cases and controls. p values were
from Wilcoxon signed rank test and values < 0.05 are bolded. The number of case/control pairs for
admissions caused by ADRs and admissions with but not caused by ADRs were 76 and 37, respectively. For
both case definitions, the control group was selected from admission with no ADRs at admission
aCIs are approximately but at least 95%, due to the discrete nature of the data used in estimation of
nonparametric CIs
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may have overlapping conditions. Also, not all patients with
the indications for the selected drugs may be actually
receiving it, especially for neuropsychiatric disorders. For
example, only 27% of patients with a major depressive
disorder consulted a doctor [37]. Finally, death (which
occurred in one patient with admission caused by ADR) or
reduced quality of life incurs no additional cost in our
analysis but are clearly important considerations to patients.
With decreasing genotyping costs, a unit cost of a pre-
emptive PGx test on the order of US$114 is quite achiev-
able. A comprehensive PGx panel (which need not be
limited to one single technology) that includes all actionable
PGx markers can also prevent cases of rare but serious and
expensive ADRs such as SJS/TEN, which can cost from US
$1740 to US$25,540 per episode [38]. Patients requiring
carbamazepine can potentially derive more benefit for no
Table 5 Calculation of
breakeven cost of pre-emptive
PGx testing
Value, US$ Remarks Reference
Potential savings by PGx testinga
Within current study
Warfarin ADRs $27,295 Efficacy of PGx (31.5%) x total cost
for these ADRs (US$86,650)
[23–26]
Clopidogrel ADRs $14,831 Efficacy of PGx (38.4%) x total cost
for these ADRs (US$38,621)
[27, 28]
Chemotherapeutic drug ADRsb $51,127 Efficacy of PGx (80.8%c) x total cost
for these ADRs (US$63,276)
[29]
Neuropsychiatric drug ADRs $3006 Efficacy of PGx (47.2%) x total cost
for these ADRs (US$6368)
[30]
Total $96,258
Estimated total annual cost nationwide $28,376,709 Using no. of adult admissions in 2016
(467,936) and proportion of non-
elective admission= 63%
[2, 43]
Number of patients at risk of ADRs due to
the 4 drugs/drug classes in 2016
Estimated number of patients with
conditionsd
Venous thromboembolism 4099 Indication for warfarin [44]
Atrial fibrillation 22692 [45]
Heart valve replacement due to aortic
stenosis
81 [46]
Myocardial infarction 15331 Indication for clopidogrel [47]
Ischemic stroke 8583 [48]
Cancer 21176 Indication for chemotherapeutic drugs [49]
Use of anti-depressants and
benzodiazepines
95149 Indication for neuropsychiatric drugs [37]
Bipolar disorder 28545 [50]
Obsessive compulsive disorder 52332 [51]
Total 247988
Breakeven cost of pre-emptive PGx test $114 Estimated total annual cost nationwide
/ number of patients at risk of ADRs
due to the 4 drugs/drug classes in 2016
aThe efficacy of PGx for each drug(s) was the median of % improvement in ADR outcomes for prospective
trials of PGx testing vs. no testing. For warfarin, only ADRs and INR > 4 were considered, and for
clopidogrel only bleeding ADRs were considered. All-cause mortality was excluded as it is not a specific
ADR
bChemotherapeutic drugs with PGx association were included bevacizumab, capecitabine, cisplatin,
cyclophosphamide, cytarabine, doxorubicin, methotrexate, oxaliplatin, paclitaxel, vinblastine and vincristine
cFor fluoropyrimidines
dNumber of patients with each condition was estimated using age-specific or total (adult) incidences or
prevalences and the population structure of the resident adult population of Singapore in 2016 and then
extrapolated to the total population. See Table S3 for more details
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additional cost over the single HLA-B*15:02 test, which
currently costs SGD200 (~US$145) [12]. The amount that
patients are willing to pay may also be much more than US
$114. A recent discrete choice experiment among Singa-
poreans at high risk of developing gout found that two-
thirds are risk averse and are willing to pay SGD438 (~US
$317) for a modest risk reduction of life-threatening ADRs
from one in 600 to one in 1000, and even more for further
risk reduction [15].
There are several limitations to our study. Firstly, the
number of patients with ADRs at admission is relatively
small. This might have affected the precision of our cost
calculations. Secondly, the data was from a single institu-
tion and the types of patients seen at SGH could be different
from that in other hospitals in Singapore. Therefore, the
extrapolated costs may be under- or over-estimated. How-
ever, that ADR survey was the most comprehensive to date
in terms of patient characteristics. Thirdly, causality
assessment of ADRs is subjective. However, we have
reduced this by having two independent assessors and a
third one to resolve any discrepancies. Fourthly, we have
only considered cost savings with four drugs or drug clas-
ses. Potential savings were likely to be underestimated as
other drug-gene pairs with substantial scientific evidence
were not included. Fifthly, additional costs arising from use
of alternative drugs due to PGx testing results were not
taken into account in the calculation. However, the majority
of drugs involved in the ADRs we considered require dose
reduction instead of more expensive alternative drugs so
cost estimates may not be affected significantly. It is pos-
sible that treatment response may be suboptimal if doses are
reduced and further costs incurred as a result. However,
PGx testing is aimed at optimizing response (INR) for
warfarin, and PGx trials for chemotherapeutic and neu-
ropsychiatric drugs have demonstrated similar response
despite dose reduction [29, 30]. Sixthly, we assumed that
the proportion of admissions avoided was the percentage
improvement in outcomes from PGx trials but the rela-
tionship between the two may not be linear. For example, a
50% reduction in ADRs due to PGx testing may not
translate to 50% reduction in ADR-related hospitalization,
depending on the type of ADRs. Seventhly, the efficacy of
PGx testing for chemotherapeutic drugs was inferred from
data for fluoropyrimidines only. Lastly, the estimation of the
number of patients receiving the four drugs/drug classes
(denominator) in our hypothetical PGx testing involved
calculations using the resident population structure and
extrapolation to the total population because the potential
cost savings (numerator) were extrapolated using the total
number of non-elective hospital admissions in Singapore,
which was derived from both residents and non-residents.
The denominator could be inaccurate due to the lack of
information about the population structure of non-residents.
However, we believe the non-resident population to be
younger as they are mostly students or people on work
permits, so we would have likely over-estimated the number
needed to test, which would give a more conservative
estimate of the breakeven cost.
In conclusion, the costs of 81 cases of ADR-induced
hospitalizations in a study of 1000 random, non-elective
adult admissions was US$570,400, and bleeding/elevated
INR ADRs were significantly more expensive than other
ADRs. Admissions caused by or with ADRs incurred
higher laboratory costs compared to admissions without
ADRs. Finally, the estimated breakeven cost of a pre-
emptive PGx test for patients needing warfarin, clopidogrel,
chemotherapeutic, or neuropsychiatric drugs was US$114.
These results suggest that future studies designed to directly
measure the clinical and cost impact of a pre-emptive
genotyping program will help inform clinical practice and
health policy decisions.
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